A Houston-based fintech company has taken a huge step in the right direction for growth. Getty Images

Houston-based fintech company HighRadius Corp. has forged a partnership with Canadian conglomerate Thomson Reuters Corp. that will open up more markets for its enterprise software-as-a-service.

The partnership equips HighRadius to tap into the global network of Confirmation.com, a unit of Thomson Reuters. Confirmation's network features more than 1,000 banks. Credit managers at those banks will be able to use HighRadius' software to automate the credit process for online credit applications.

"This partnership will allow us to expand our credit inquiry solution to new markets," Mark Portanova, Confirmation.com's vice president of sales for the Americas, says in a release. "We will enhance workflows, reporting capabilities, and client authorization processes within the HighRadius platform. These measures will progress the traditionally slow, manual, and time-consuming credit approval processes … ."

HighRadius' AI-powered software is designed to streamline accounts-receivable and cash-management processes. For instance, HighRadius' Cash Application software relies on AI to comb through documents like emails and invoices to automatically match incoming payments with customers' accounts.

Sayid Shabeer, chief product officer at HighRadius, says the company's suite of product ultimately lets companies free up millions of dollars in working capital and reallocate employees' time to higher-value tasks.

Among HighRadius' customers are corporate heavyweights like healthcare giant Johnson & Johnson, apparel maker adidas, food company Danone, and Dr Pepper Snapple Group. In January, HighRadius reported it had passed the 350-customer mark last year and doubled the size of its European workforce.

"2018 was the year that the bets we've been making over the last few years started to pay off in scale," Sashi Narahari, founder and CEO of HighRadius, says in a release.

Among HighRadius' competitors are Billtrust, Rimilia Holdings, Cforia Software, and Financial National Information Services. The global market for credit management software is forecast to exceed $2.1 billion by 2022, up from $636.4 million in 2017.

HighRadius, founded in 2006, employs more than 1,000 people in North America, Europe, and Asia. Since its inception, HighRadius has raised more than $50 million from Philadelphia-based Susquehanna Growth Equity, and has collected strategic investments from banking behemoths Citi and PNC.

HighRadius recently hired Jon Keating as vice president and general manager of its Europe, Middle East, and Africa (EMEA) markets. Keating most recently was chief sales officer at San Francisco fintech company Taulia. Earlier in the year, the company tapped SaaS veteran Natalie Fedie as vice president of customer success to help propel its global growth.

"HighRadius continues to invest in talent across Europe and Asia to fuel its growth plans and keep ahead of the innovation curve," Shabeer says.

Last year, HighRadius moved its headquarters to 200 Westlake Park Blvd. in the Energy Corridor. More than 150 employees relocated there. HighRadius subleases the space from BP America.

"The expansion of HighRadius into the Katy area represents another high-tech company choosing to mature in our community," Lance LaCour, president and CEO of the Katy Area Economic Development Corp., said at the time. "HighRadius is projected to have an estimated regional economic impact of over $600 million over a five-year period."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.